Business
Sernova's Principal Investigator to Present Interim Data from the Company's Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association
(via TheNewswire) LONDON, ONTARIO - TheNewswire - June 27, 2019 - Sernova...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova's Principal Investigator to Present Interim Data from the Company's Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant Association(via TheNewswire)\n \n \nLONDON, ONTARIO - TheNewswire - June 27, 2019 - Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company is pleased to announce that Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, will present, in an oral podium session, early preliminary data and observations from Sernova's ongoing clinical trial, entitled A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch(TM) for Clinical Islet Transplantation, at the 17th World Congress of the International Pancreas and Islet Transplantation Association (IPITA) which is being held July 2 - 5, 2019 in Lyon, France.\n\n\n \n Dr. Witkowski is scheduled to deliver his address during a symposium on islet transplantation on July 3, 2019 at 10:45 a.m. (CET) at Lyon's Catholic University in the Amphitheater Merieux 1 & 2. Further details on the scientific program can be found on the conference website (http://www.ipita2019.org/programme-scientifique). \n\n\n \nABOUT IPITA \n\n\n \nThe International Pancreas and Islet Transplantation Association aims to serve the pancreas and islet transplant scientific community in providing a forum for the open exchange of knowledge and expertise in order to facilitate the advancement of the clinical practice of pancreas and islet transplantation for the treatment of human diabetes.(https://www.tts.org/ipita/home)\n\n\n \nABOUT SERNOVA'S CLINICAL TRAIL\n\n\n \nSernova is conducting a Phase I/II non-randomized, unblinded, single arm, company-sponsored trial, to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. \n\n\n \nEligible subjects are implanted with Cell Pouches. Following development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression and a dose of purified islets, under strict release criteria, transplanted into the Cell Pouch. \n\n\n \nA sentinel pouch is removed for an early assessment of ...